JP2018502135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502135A5 JP2018502135A5 JP2017537449A JP2017537449A JP2018502135A5 JP 2018502135 A5 JP2018502135 A5 JP 2018502135A5 JP 2017537449 A JP2017537449 A JP 2017537449A JP 2017537449 A JP2017537449 A JP 2017537449A JP 2018502135 A5 JP2018502135 A5 JP 2018502135A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- integer
- compound
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims 4
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- APZVUWUBOBSYOC-UHFFFAOYSA-N 4-(2-phenylphenyl)-2H-benzotriazole Chemical group C1=CC=CC=C1C1=CC=CC=C1C1=CC=CC2=C1N=NN2 APZVUWUBOBSYOC-UHFFFAOYSA-N 0.000 claims 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical group C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims 2
- -1 Biphenylyl Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 CC(CCC#CNC)(C=C(C=C1)c2c(*)cc3[n]c(OC(COC45)C4OCC5O)nc3n2)*=C1C(*=CC(*)=C1)=CC1(C)F Chemical compound CC(CCC#CNC)(C=C(C=C1)c2c(*)cc3[n]c(OC(COC45)C4OCC5O)nc3n2)*=C1C(*=CC(*)=C1)=CC1(C)F 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15151419.7 | 2015-01-16 | ||
| EP15151419 | 2015-01-16 | ||
| EP15167116 | 2015-05-11 | ||
| EP15167116.1 | 2015-05-11 | ||
| PCT/EP2016/050557 WO2016113299A1 (en) | 2015-01-16 | 2016-01-13 | New azabenzimidazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502135A JP2018502135A (ja) | 2018-01-25 |
| JP2018502135A5 true JP2018502135A5 (enExample) | 2019-02-28 |
| JP6612881B2 JP6612881B2 (ja) | 2019-11-27 |
Family
ID=55129871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017537449A Active JP6612881B2 (ja) | 2015-01-16 | 2016-01-13 | 新規なアザベンゾイミダゾール誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10053471B2 (enExample) |
| EP (1) | EP3245212B1 (enExample) |
| JP (1) | JP6612881B2 (enExample) |
| WO (1) | WO2016113299A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016068099A1 (ja) | 2014-10-28 | 2016-05-06 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する複素環誘導体 |
| CA3014858A1 (en) | 2016-02-26 | 2017-08-31 | Shionogi & Co., Ltd. | 5-phenylazaindole derivative having ampk-activating activity |
| CA3024090A1 (en) * | 2016-05-20 | 2017-11-23 | Shionogi & Co., Ltd. | 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having ampk activation effect |
| CN106278970A (zh) * | 2016-08-09 | 2017-01-04 | 孙冉 | 一种二芳基亚砜胺类化合物的合成方法 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122021002201A8 (pt) * | 2011-02-25 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença |
| WO2014069426A1 (ja) * | 2012-10-31 | 2014-05-08 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 |
| CN105377857B (zh) * | 2013-07-17 | 2018-04-10 | 勃林格殷格翰国际有限公司 | 新颖氮杂苯并咪唑衍生物 |
-
2016
- 2016-01-13 WO PCT/EP2016/050557 patent/WO2016113299A1/en not_active Ceased
- 2016-01-13 EP EP16700459.7A patent/EP3245212B1/en active Active
- 2016-01-13 JP JP2017537449A patent/JP6612881B2/ja active Active
- 2016-01-13 US US15/543,242 patent/US10053471B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502135A5 (enExample) | ||
| RU2309946C2 (ru) | Новые соединения в качестве противовоспалительных, иммуномодулирующих и противопролиферативных агентов | |
| JP2013529210A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2009529541A5 (enExample) | ||
| WO2013022278A3 (en) | N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
| JP2009530399A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2008531520A5 (enExample) | ||
| NZ598294A (en) | Heterocyclic compounds for the inhibition of pask | |
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| JP2016500063A5 (enExample) | ||
| JP2009263394A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2018135343A5 (enExample) | ||
| JP2017506666A5 (enExample) | ||
| JP2017523226A5 (enExample) | ||
| PH12018500261A1 (en) | Azole benzene derivative | |
| JP2016528273A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| JP2020517619A5 (enExample) | ||
| JP2016527223A5 (enExample) | ||
| JP2007500222A5 (enExample) |